UY34812A - Método para el tratamiento del cáncer de pulmón de células no pequeñas - Google Patents

Método para el tratamiento del cáncer de pulmón de células no pequeñas

Info

Publication number
UY34812A
UY34812A UY0001034812A UY34812A UY34812A UY 34812 A UY34812 A UY 34812A UY 0001034812 A UY0001034812 A UY 0001034812A UY 34812 A UY34812 A UY 34812A UY 34812 A UY34812 A UY 34812A
Authority
UY
Uruguay
Prior art keywords
treatment
nucleotides
lung cancer
small cells
patient
Prior art date
Application number
UY0001034812A
Other languages
English (en)
Spanish (es)
Inventor
Duksin Chen
Tessler Shoshi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34812A publication Critical patent/UY34812A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001034812A 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas UY34812A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
UY34812A true UY34812A (es) 2013-12-31

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034812A UY34812A (es) 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300257T3 (es) 1999-02-26 2008-06-16 The University Of British Columbia Terapia antisentido contra trpm-2.
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
ES3041855T3 (en) 2010-05-08 2025-11-17 Univ California Radiofrequency sensing method and apparatus for early detection of pressure ulcers
WO2012123823A1 (en) 2011-03-15 2012-09-20 The University Of British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
SG11201810082VA (en) * 2016-05-13 2018-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
DK3515306T3 (da) 2017-02-03 2025-01-27 Bbi Medical Innovations Llc Måling af modtagelighed for diabetiske fodsår
PT3515296T (pt) 2017-02-03 2023-12-18 Bbi Medical Innovations Llc Medição da viabilidade do tecido
JP6900477B2 (ja) 2017-02-03 2021-07-07 ブルーイン、バイオメトリクス、リミテッド、ライアビリティー、カンパニーBruin Biometrics, Llc コンパートメント症候群を評価するための装置、およびコンパートメント症候群を検出するためのコンピュータ可読媒体
AU2018368709C1 (en) * 2017-11-16 2025-07-17 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
SI3749181T1 (sl) 2018-02-09 2024-06-28 Bruin Biometrics, LLC, Odkrivanje poškodb na tkivu
CN117596814A (zh) 2018-10-11 2024-02-23 布鲁恩生物有限责任公司 具有一次性元件的装置
WO2022169850A1 (en) 2021-02-03 2022-08-11 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
MX2010014228A (es) * 2008-06-18 2011-03-29 Abbott Laboratories Star Metodos y productos de diagnostico del p/gf-1 acompañante.
EP2709673A4 (en) * 2011-05-19 2014-12-17 Teva Pharma METHOD FOR THE TREATMENT OF NON-SMALL CELLULAR CANCER

Also Published As

Publication number Publication date
CN104684564A (zh) 2015-06-03
EP2849761A1 (en) 2015-03-25
KR20150024843A (ko) 2015-03-09
AU2013262589A1 (en) 2015-01-22
WO2013173757A8 (en) 2015-04-30
CA2874092A1 (en) 2013-11-21
BR112014028787A2 (pt) 2017-06-27
US20130310440A1 (en) 2013-11-21
EA201492148A1 (ru) 2015-04-30
JP2015522542A (ja) 2015-08-06
PH12014502569A1 (en) 2015-01-21
TW201402132A (zh) 2014-01-16
AR091090A1 (es) 2014-12-30
IN2014DN10390A (enExample) 2015-08-14
IL235459A0 (en) 2014-12-31
WO2013173757A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
Kim et al. MicroRNA targeting by quercetin in cancer treatment and chemoprotection
Shankar et al. Epigenetic modifications by dietary phytochemicals: implications for personalized nutrition
Li et al. Targeting long non-coding RNAs in cancers: progress and prospects
MX2021005389A (es) Formulaciones de nanoparticulas lipidicas.
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
MX2024005652A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
Schnekenburger et al. Epigenetic modulators from “The Big Blue”: A treasure to fight against cancer
MX2013013384A (es) Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.
MX359548B (es) Agentes de iarn modificados.
AR091004A1 (es) Arn en horquilla corta bifuncional (bi-arnhc) especifico de mutaciones de nucleotidos individuales en k-ras
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
CO7170127A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 m(lag-3) y usos de los mismos
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
EA201590070A1 (ru) ИНГИБИТОРЫ МИКРОРНК СЕМЕЙСТВА miR-15
PE20142362A1 (es) Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
IN2014CN03921A (enExample)
CY1117000T1 (el) Ενζυματικη αντικαρκινικη θεραπεια
ES2651147T3 (es) Oligonucleótidos para modular la expresión génica y usos de los mismos
AR098819A1 (es) Método y composiciones para el control de insectos plaga en plantas por medio del silenciamiento de genes de la familia de la quitina sintasa y de la vitelogenina así como alternativamente por la expresión del gen de una toxina cry
AR083445A1 (es) siARN CONTRA LA FIBROSIS
AR095416A1 (es) Tratamiento con cutirsen que presenta una toxicidad reducida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528